title: BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model.
abstract: OBJECTIVE
  The BRCAPRO model, used to predict a family's likelihood of carrying a BRCA1 or BRCA2 mutation, was designed using mutation frequencies of white and Ashkenazi Jewish populations, and may not be applicable to other populations. BRCAPRO was recently validated in African Americans, although has yet to be examined in Hispanics. This retrospective study reports the mutation frequency and spectrum of BRCA1 and BRCA2 mutations in a Hispanic population and evaluates the BRCAPRO model in Hispanics.
  
  
  METHODS
  A descriptive analysis of mutation frequency and spectrum was performed for Hispanic patients who underwent BRCA1 and BRCA2 genetic testing at a single institution. For comparative analysis of the BRCAPRO risk model, Hispanic patients who underwent comprehensive analysis were compared with white controls using area under the receiver operating characteristic curves (AUROC).
  
  
  RESULTS
  Fourteen Hispanic individuals who underwent comprehensive analysis were identified to carry a mutation in BRCA1 or BRCA2 (17.9%; 95% CI, 10.2% to 28.3%) and seven individuals had a variant of uncertain significance (9.0%; 95% CI, 12.0% to 30.8%). A total of eight different mutations and three variants were observed within the entire Hispanic population. When evaluating the performance of the BRCAPRO model, the AUROC for Hispanics was 0.774 (95% CI, 0.63 to 0.90), compared with the AUROC of 0.770 (95% CI, 0.65 to 0.89) for whites.
  
  
  CONCLUSIONS
  Deleterious BRCA1 and BRCA2 mutations occur at considerable frequency within the Hispanic population, many of which have been identified previously in other ethnic populations. The BRCAPRO model appears to perform equally well in Hispanics as in whites.
authors.affiliation: Center for Medical Genetics, Evanston Northwestern Healthcare, Evanston, IL, USA.
authors.forename: Kristen J
authors.initials: KJ
authors.lastname: Vogel
authors.forename: Deann P
authors.initials: DP
authors.lastname: Atchley
authors.forename: Julie
authors.initials: J
authors.lastname: Erlichman
authors.forename: Kristine R
authors.initials: KR
authors.lastname: Broglio
authors.forename: Kaylene J
authors.initials: KJ
authors.lastname: Ready
authors.forename: Vicente
authors.initials: V
authors.lastname: Valero
authors.forename: Christopher I
authors.initials: CI
authors.lastname: Amos
authors.forename: Gabriel N
authors.initials: GN
authors.lastname: Hortobagyi
authors.forename: Karen H
authors.initials: KH
authors.lastname: Lu
authors.forename: Banu
authors.initials: B
authors.lastname: Arun
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000208:ethnology / Q000235:genetics*; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006630:Hispanic or Latino; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000208:ethnology / Q000235:genetics*; D015995:Prevalence; D012372:ROC Curve; D012306:Risk; D014481:United States